Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies
Philipp A. Ilinykh(Houston Methodist), Alexander Bukreyev(Galveston College), Natalia A. Kuzmina(Galveston College), Kai Huang(Galveston College), Pavlo Gilchuk(AstraZeneca (Japan)), Larry Zeitlin(Mapp Biopharmaceutical (United States)), James E. Crowe(Vanderbilt University Medical Center), Edgar Davidson(Integral Molecular (United States)), Galit Alter(Ragon Institute of MGH, MIT and Harvard), Colette Pietzsch(Galveston College), Erica Ollmann Saphire(La Jolla Institute for Immunology), Rodrigo I. Santos(Universidade de São Paulo), Marcus M. Karim(Ragon Institute of MGH, MIT and Harvard), Michelle Meyer(Galveston College), Mallorie E. Fouch(Integral Molecular (United States)), Bronwyn M. Gunn(Washington State University), Jenny Liang(Integral Molecular (United States)), Diptiben Parekh(Scripps Research Institute)
Cited by 81
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981